Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma

NCT03185325 | Completed

• 1 other identifier: AssiutUniversity
• Study Type: observational
• Target: 62
• Locations: 1 country
• Sites: 1

Brief Summary

Lymphomas are hematological malignancies, which are divided into non-Hodgkin lymphoma and Hodgkin lymphoma. Non hodgkin lymphoma is a lymphoma-derived malignancy that makes up about 90% of all malignant lymphoma. According to its origin, non hodgkin lymphoma is classified into B-cell non hodgkin lymphoma and T-cell non hodgkin lymphoma. The most common types are follicular lymphoma, and diffuse large B-cell lymphoma. Lymphomas are types of cancer that develops from lymphocytes, a type of white blood cell. Diagnosis is by examination of a bone marrow or lymph node biopsy. Non hodgkin lymphoma mortality has increased in recent years and has become the seventh most frequently occurring cancer.

Conditions

Non Hodgkin Lymphoma

Outcome Measures

Primary Outcomes (1)

• mean difference of micro ribosomal nucleic acid 155 expression levels between samples of both non hodgkin lymphoma patients and healthy controls

  measuring levels of micro ribosomal nucleic acid 155 in peripheral blood and bone marrow samples of non hodgkin lymphoma patients and in peripheral blood samples of healthy controls

  6 months

Secondary Outcomes (1)

• Mean difference of levels of expression of micro ribosomal nucleic acid 155 between peripheral blood and bone marrow samples of non hodgkin lymphoma patients

  6 months

Study Arms (2)

Non hodgkin lymphoma patients

bone marrow puncture and venous blood samples

Other: bone marrow puncture and venous blood samples

healthy voulnteers

venous blood samples

Other: venous blood samples

Interventions

bone marrow puncture and venous blood samples OTHER

bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients

Non hodgkin lymphoma patients

venous blood samples OTHER

venous blood samples are collected in healthy voulnteers

healthy voulnteers

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Non hodgkin lymphoma patients who are newly diagnosed or relapsed cases and healthy controls who have no other heamatological malignancies

You may qualify if:

• Non hodgkin lymphoma patients of any age or sex.
• healthy volunteers within the same range of age.

You may not qualify if:

• patients with any other haematological malignancy.

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

AssiutU

Asyut, Egypt

Location

Related Publications (4)

• Ekstrom-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma--a review. Acta Oncol. 2006;45(3):258-71. doi: 10.1080/02841860500531682.

  PMID: 16644568 BACKGROUND

• Nogai H, Dorken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol. 2011 May 10;29(14):1803-11. doi: 10.1200/JCO.2010.33.3252. Epub 2011 Apr 11.

  PMID: 21483013 BACKGROUND

• Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000 Aug 1;96(3):808-22. No abstract available.

  PMID: 10910891 BACKGROUND

• Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012 Dec;6(6):590-610. doi: 10.1016/j.molonc.2012.09.006. Epub 2012 Oct 9.

  PMID: 23102669 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral blood and bone marrow samples for micro ribonucleic acid 155 extraction

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Merna W Narouz

  Assiut University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: principal investigator

Study Record Dates

• First Submitted: June 10, 2017
• First Posted: June 14, 2017
• Study Start: March 10, 2018
• Primary Completion: April 24, 2019
• Study Completion: December 24, 2019
• Last Updated: January 13, 2021

Record last verified: 2020-01

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)